Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Conditions:   NSCLC;   Adenocarcinoma;   Squamous Cell Carcinoma Interventions:   Drug: Anlotinib combined with pemetrexed and carboplatin, phase I;   Drug: Anlotinib combined with paclitaxel and carboplatin, phase I;   Drug: Anlotinib combined with pemetrexed and carboplatin, phase II;   Drug: Anlotinib combined with paclitaxel and carboplatin, phase II Sponsor:   Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials